HCMV promotes viral reactivation through the coordinated regulation of Notch signaling by UL8 and miR-UL36

Aaron Dirck, Nicole L. Diggins, Wilma Perez, Christopher J. Parkins, Michael Daily, Rebekah Turner, Luke Slind, Linh K. Nguyen, Daniel Malouli, Kui Wu, Meaghan H. Hancock, Patrizia CaposiomBio 2026 · DOI

TL;DR

Human cytomegalovirus (HCMV) hijacks host cell differentiation pathways to reactivate from latency. This study reveals that HCMV uses two viral components, protein UL8 and microRNA miR-UL36, to suppress the Notch signaling pathway, which normally acts as a barrier to reactivation. By inhibiting Notch signaling, HCMV creates an environment conducive to its own replication, offering potential therapeutic targets for preventing disease in immunocompromised individuals.

What Problem Does This Paper Address?

Human cytomegalovirus (HCMV) is a common virus that establishes lifelong latency, particularly in hematopoietic stem cells (HPCs). Reactivation of HCMV, which can cause severe illness in immunocompromised individuals like transplant recipients, is closely tied to the differentiation of these HPCs. While the general concept of differentiation influencing reactivation is known, the specific viral mechanisms that control this process and overcome the host's intrinsic barriers to viral replication remain largely unclear. This paper investigates how HCMV manipulates host cell signaling pathways, specifically the Notch pathway, to promote its reactivation from latency.

Methods

The researchers employed a multi-pronged approach:

  • In vitro cell culture models: They used human CD34+ HPCs and human dermal fibroblasts (NHDFs) to study HCMV infection, latency, and reactivation.
  • Viral mutants: They generated and utilized HCMV mutants lacking specific viral genes (e.g., $\Delta$UL8) or with altered protein sequences (e.g., UL8 Y305/314A) to dissect the roles of UL8 and miR-UL36.
  • Pharmacological inhibition: They used CB-103, a selective inhibitor of Notch signaling, to probe the pathway's role in HCMV infection and reactivation.
  • Molecular biology techniques: This included quantitative RT-PCR to measure gene expression, Western blotting to assess protein levels, immunoprecipitation to study protein interactions, and luciferase assays to evaluate Notch pathway activity.
  • Proximity-dependent biotinylation (BioID-MS): This technique was used to identify host proteins in close proximity to the viral protein UL8, helping to uncover potential interactions and pathways involved.
  • Humanized mouse model: To validate findings in vivo, they used NSG mice engrafted with human CD34+ HPCs and infected with HCMV.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Notch signaling as a barrier: The study firmly establishes the Notch signaling pathway as a critical host defense mechanism that normally suppresses HCMV replication and reactivation in HPCs.
  • Dual viral attack on Notch: HCMV doesn't rely on a single mechanism to overcome this barrier. It employs both a viral protein (UL8) and a viral microRNA (miR-UL36) to disrupt Notch signaling.
  • UL8's direct degradation of Notch3: UL8 directly targets the Notch3 receptor for degradation via the endosomal/lysosomal pathway, a process dependent on specific tyrosine motifs within UL8. This is a novel mechanism of viral interference with host signaling.
  • miR-UL36's post-transcriptional control: miR-UL36 acts at the post-transcriptional level to reduce the expression of both the Notch3 receptor and RBPJ, a key transcription factor in the Notch pathway.
  • Synergistic effect for reactivation: The combined action of UL8 and miR-UL36 creates a potent "Wnt-ON/Notch-OFF" environment, which is crucial for promoting HPC differentiation and enabling HCMV reactivation.
  • Therapeutic implications: The findings highlight that inhibiting Notch signaling can overcome the defects caused by UL8 or miR-UL36 mutants, suggesting that targeting the Notch pathway could be a viable strategy to prevent HCMV reactivation and disease.

Key Results

  • Inhibition of Notch signaling with CB-103 significantly enhanced HCMV replication in latent HPCs and promoted viral reactivation.
  • UL8 directly interacts with Notch3 and promotes its degradation, with specific tyrosine residues (Y305/314) in UL8 being critical for this interaction and degradation.
  • Mutating these tyrosine residues in UL8 (UL8 Y305/314A) impaired viral reactivation in vitro and in humanized mice, but this defect could be rescued by Notch inhibition.
  • miR-UL36 was shown to reduce Notch3 and RBPJ protein levels, thereby suppressing Notch signaling.
  • A virus lacking miR-UL36 (AmiR-UL36) exhibited impaired reactivation in vitro and in humanized mice, which was also rescued by Notch inhibition.
  • Both UL8 and miR-UL36 are essential for efficient HCMV reactivation, and their roles appear to be non-redundant.

Limitations and Future Work

  • Mechanism of miR-UL36: While miR-UL36 was shown to reduce Notch3 and RBPJ levels, no direct binding sites were found in their 3'UTRs, suggesting a non-canonical or indirect regulatory mechanism that warrants further investigation.
  • Cooperation between UL8 and miR-UL36: The precise mechanistic details of how UL8 and miR-UL36 cooperate to dismantle Notch signaling remain to be fully elucidated.
  • Additional targets: The study raises questions about whether miR-UL36 targets other host transcripts and if other viral miRNAs contribute to Notch pathway regulation.
  • Other Notch receptors: The study focused on Notch3. It's unclear if UL8 affects other Notch receptors or components of the Notch pathway.
  • Host response vs. viral stimulation: The early activation of Notch target genes upon HCMV infection could be a host response or direct viral stimulation, which requires further investigation.
  • Therapeutic strategies: While promising, further research is needed to translate these findings into effective therapeutic strategies for preventing HCMV disease.

Summary updated

Abstract

Human cytomegalovirus (HCMV) establishes latency in CD34<sup>+</sup> hematopoietic progenitor cells (HPCs), where reactivation is intimately linked to cellular differentiation. We demonstrate that the Notch signaling pathway, a key regulator of stem cell maintenance and differentiation, functions as a barrier to HCMV reactivation. Two viral gene products, UL8 and miR-UL36, modulate this pathway during reactivation. UL8 promotes degradation of the Notch3 receptor via the endosomal/lysosomal pathway, dependent on two tyrosine-based motifs (Y305/314) in its cytoplasmic tail. A UL8 mutant lacking these motifs fails to degrade Notch3, resulting in sustained Notch signaling and impaired reactivation <i>in vitro</i> and in humanized mice. Similarly, miR-UL36 reduces the expression of Notch3 and the Notch transcription factor recombination signal binding protein for immunoglobulin kappa J region (RBPJ), suppressing Notch signaling. Deletion of miR-UL36 inhibits reactivation, but this defect, like that of the UL8 mutant, can be rescued by pharmacologic Notch inhibition. Thus, HCMV employs multiple gene products to suppress Notch signaling and promote conditions conducive to reactivation. These findings reveal how HCMV manipulates host differentiation pathways to control latency and suggest therapeutic strategies to prevent viral recurrence in immunocompromised patients.IMPORTANCEHuman cytomegalovirus (HCMV) establishes lifelong latency, posing significant risks to transplant recipients and other immunocompromised individuals. Reactivation depends on progenitor cell differentiation; however, the viral mechanisms governing this process remain unclear. We identify Notch signaling as a major inhibitory pathway to reactivation and show that HCMV uses UL8 and miR-UL36 to suppress this pathway. UL8 degrades Notch3, while miR-UL36 downregulates Notch3 and RBPJ, together reducing Notch signaling and enabling reactivation. Mutant viruses lacking these regulators fail to reactivate efficiently, but this can be reversed by pharmacological inhibition of Notch. These findings establish Notch pathway suppression as a critical viral strategy for reactivation and highlight potential therapeutic targets for preventing HCMV disease.
BibTeX
@inproceedings{dirck2026hcmv,
  author = {Aaron Dirck and Nicole L. Diggins and Wilma Perez and Christopher J. Parkins and Michael Daily and Rebekah Turner and Luke Slind and Linh K. Nguyen and Daniel Malouli and Kui Wu and Meaghan H. Hancock and Patrizia Caposio},
  title = {{HCMV promotes viral reactivation through the coordinated regulation of Notch signaling by UL8 and miR-UL36}},
  booktitle = {mBio},
  year = {2026},
  doi = {10.1128/mbio.03377-25},
}
Figure